Eiger BioPharmaceuticals (NASDAQ: EIGR) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Eiger BioPharmaceuticals to related companies based on the strength of its profitability, valuation, analyst recommendations, dividends, earnings, institutional ownership and risk.


This table compares Eiger BioPharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eiger BioPharmaceuticals N/A -128.94% -88.88%
Eiger BioPharmaceuticals Competitors -3,682.34% -415.70% -47.90%

Insider & Institutional Ownership

59.9% of Eiger BioPharmaceuticals shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 28.8% of Eiger BioPharmaceuticals shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Eiger BioPharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Eiger BioPharmaceuticals N/A -$46.28 million -1.85
Eiger BioPharmaceuticals Competitors $207.12 million -$2.38 million 0.34

Eiger BioPharmaceuticals’ peers have higher revenue and earnings than Eiger BioPharmaceuticals. Eiger BioPharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Eiger BioPharmaceuticals has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500. Comparatively, Eiger BioPharmaceuticals’ peers have a beta of 1.67, meaning that their average stock price is 67% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Eiger BioPharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eiger BioPharmaceuticals 0 0 4 0 3.00
Eiger BioPharmaceuticals Competitors 780 2920 6372 144 2.58

Eiger BioPharmaceuticals presently has a consensus target price of $32.60, indicating a potential upside of 210.48%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 8.79%. Given Eiger BioPharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Eiger BioPharmaceuticals is more favorable than its peers.


Eiger BioPharmaceuticals beats its peers on 8 of the 12 factors compared.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.